Kiniksa Pharmaceuticals International PLC (KNSA)
21.11
-0.06
(-0.30%)
USD |
NASDAQ |
Dec 04, 16:00
21.11
0.00 (0.00%)
After-Hours: 20:00
Kiniksa Pharmaceuticals International Revenue (Quarterly): 112.21M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 112.21M |
| June 30, 2024 | 108.63M |
| March 31, 2024 | 79.86M |
| December 31, 2023 | 83.40M |
| September 30, 2023 | 67.05M |
| June 30, 2023 | 71.47M |
| March 31, 2023 | 48.34M |
| Date | Value |
|---|---|
| December 31, 2022 | 61.88M |
| September 30, 2022 | 99.14M |
| June 30, 2022 | 26.97M |
| March 31, 2022 | 32.19M |
| December 31, 2021 | 18.74M |
| September 30, 2021 | 12.10M |
| June 30, 2021 | 7.704M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
7.704M
Minimum
Jun 2021
112.21M
Maximum
Sep 2024
59.26M
Average
64.46M
Median
Revenue (Quarterly) Benchmarks
| Pfizer Inc | 17.70B |
| NovaBay Pharmaceuticals Inc | 2.441M |
| Palatin Technologies Inc | -- |
| iBio Inc | -- |
| Theriva Biologics Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -12.69M |
| Total Expenses (Quarterly) | 121.87M |
| EPS Diluted (Quarterly) | -0.18 |
| Enterprise Value | 1.305B |
| Gross Profit Margin (Quarterly) | 55.96% |
| Profit Margin (Quarterly) | -11.31% |
| Earnings Yield | -0.66% |
| Normalized Earnings Yield | -0.6633 |